Montanide

OTHER8 trials

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaAcute Myelogenous Leukemia (AML)Acute Myeloid LeukemiaColorectal CancerFallopian Tube CancerLeukemiaMultiple Myeloma

Phase 1

Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors

CompletedNCT00935545

NYU Langone HealthTumors, Central Nervous System

Start: 2009-07-31End: 2014-01-31Updated: 2016-01-26

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

CompletedNCT01827137

Sellas Life Sciences GroupMultiple Myeloma

Start: 2013-04-30End: 2017-11-06Updated: 2024-09-19

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

NCT02240537

Benovus Bio, Inc.Acute Myelogenous Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS) +1

Start: 2015-01-31End: 2017-06-30Updated: 2016-04-19

Autologous OC-L Vaccine and Ovarian Cancer

TerminatedNCT02452775

Abramson Cancer Center at Penn MedicineFallopian Tube Cancer, Primary Ovarian Cancer, Primary Peritoneal Cancer

Start: 2015-05-31End: 2018-05-30Updated: 2020-04-24

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

CompletedNCT03761914

Sellas Life Sciences GroupAcute Myelogenous Leukemia, Colorectal Cancer, Ovarian Cancer +2

Start: 2019-09-30End: 2022-10-27Updated: 2024-11-19

Phase 2

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

CompletedNCT01266083

Sellas Life Sciences GroupAcute Lymphoblastic Leukemia, Acute Myeloid Leukemia

Start: 2011-01-14End: 2016-09-30Updated: 2024-11-19

Phase 3

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruitingNCT04229979

Sellas Life Sciences GroupAcute Myeloid Leukemia

Start: 2021-02-08End: 2026-12-31Updated: 2025-10-01

Unknown Phase

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

CompletedNCT00665002

H. Lee Moffitt Cancer Center and Research InstituteLeukemia

Start: 2008-06-30End: 2015-02-28Updated: 2015-02-27

Future Oncology2024-11-282 citations

A randomized, open-label study of the efficacy and safety of galinpepimut-S (GPS) maintenance monotherapy compared to investigator's choice of best available therapy (BAT) in patients with acute myeloid leukemia (AML) who have achieved complete remission (CR) after second-line salvage therapy.

Journal of Clinical Oncology2023-06-011 citations

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia

Blood Advances2018-01-31158 citations

WT1 heteroclitic epitope immunization following autologous stem cell transplantation in patients with high-risk multiple myeloma (MM).

Journal of Clinical Oncology2017-05-203 citations

Pilot trial of a WT-1 analog peptide vaccine in patients with high-risk myeloid neoplasms.

Journal of Clinical Oncology2014-05-202 citations